


Data Sheet (Cat.No.T12419)

PF-04634817 succinate

Chemical Properties

CAS No.:	2140301-98-8
Formula:	C ₂₉ H ₄₂ F ₃ N ₅ O ₇
Molecular Weight:	629.67
Appearance:	N/A
Storage:	0-4°C for short term (days to weeks), or -20°C for long term (months).



Biological Description

Description	PF-0463481 succinate is a potent and orally active dual antagonist of CCR2/CCR5 with comparable human and rodent CCR2 potency with IC ₅₀ of 20.8 nM.
Targets(IC ₅₀)	COX-2: 20.8 nM COX-5: 470 nM
In vivo	Early intervention with PF-04634817 induces an additional increase in glycated hemoglobin (HbA1c) levels[1].

Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.588 mL	7.941 mL	15.881 mL
5 mM	0.318 mL	1.588 mL	3.176 mL
10 mM	0.159 mL	0.794 mL	1.588 mL
50 mM	0.032 mL	0.159 mL	0.318 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

- Tesch GH, et al. Combined inhibition of CCR2 and ACE provides added protection against progression of diabetic nephropathy in Nos3-deficient mice. *Am J Physiol Renal Physiol*. 2019 Dec 1;317(6):F1439-F1449.
- Gale JD, et al. A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema. *Invest Ophthalmol Vis Sci*. 2018 May 1;59(6):2659-2669.
- Gale JD, et al. Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy. *Kidney Int Rep*. 2018 Aug 3;3(6):1316-1327.

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481